eISSN (Online): 2598-0580



Bioscientia Medicina: Journal of Biomedicine & Translational Research

Journal Homepage: www.bioscmed.com

Erythema Nodosum Leprosum as a Harbinger of Relapse in Multibacillary Leprosy: A Clinico-Histopathological Case Study

Benedikta Lauda[1*], Nurrachmat Mulianto[1]

[1]Department of Dermatology and Venereology, Faculty of Medicine, Universitas Sebelas Maret/Dr. Moewardi Regional General Hospital, Surakarta, Indonesia

ARTICLE INFO

Keywords:
Erythema nodosum leprosum
Histopathology
Lepromatous leprosy
Leprosy
Relapse

***Corresponding author:**
Benedikta Lauda

E-mail address:
benelauda11@gmail.com

All authors have reviewed and approved the final version of the manuscript.

https://doi.org/10.37275/bsm.v9i12.1468

A B S T R A C T

Background: Leprosy, a chronic granulomatous disease caused by *Mycobacterium leprae*, presents formidable long-term management challenges. In the post-elimination era, differentiating a true bacteriological relapse from a late-onset Erythema Nodosum Leprosum (ENL) reaction in patients who have completed multidrug therapy (MDT) is a critical diagnostic dilemma. Misdiagnosis can lead to inappropriate treatment, risking disease progression and irreversible nerve damage. **Case presentation:** A 30-year-old male presented with a severe, systemic inflammatory illness two years after completing MDT for lepromatous leprosy. His symptoms included crops of painful, erythematous nodules, fever, and arthralgia. While clinically suggestive of a severe ENL reaction, a slit-skin smear revealed a paradoxically high bacterial index (BI) of +5 with a morphological index (MI) of 0%. A skin biopsy was performed for definitive diagnosis. Histopathology revealed a dual pathology: a diffuse infiltrate of foamy macrophages typical of lepromatous leprosy, alongside a dense neutrophilic panniculitis characteristic of ENL. Crucially, Fite-Faraco staining demonstrated vast numbers of intact, solid-staining acid-fast bacilli, providing unequivocal evidence of active bacterial proliferation. **Conclusion:** This case demonstrates that a diagnostic algorithm integrating a high index of clinical suspicion with comprehensive bacteriological and histopathological methods is essential for accurately identifying relapse masked by ENL. The presence of viable bacilli confirms that ENL can be a direct clinical harbinger of relapse, mandating a dual therapeutic strategy that combines aggressive anti-inflammatory treatment with the immediate re-initiation of MDT.

1. Introduction

Leprosy, or Hansen's disease, is an ancient disease that continues to pose modern medical challenges. Caused by the slow-growing, obligate intracellular bacillus *Mycobacterium leprae*, it orchestrates a spectrum of disease driven by the host's own immune response.[1] This pathogen's unique tropism for Schwann cells and dermal macrophages results in devastating damage to the peripheral nerves and skin, leading to the characteristic deformities and disabilities that have fueled social stigma for millennia. The advent of multidrug therapy (MDT) in the 1980s revolutionized leprosy care, transforming a lifelong affliction into a curable condition.[2] The success of the World Health Organization (WHO)-led global strategy, centered on early detection and free access to MDT, has been profound, drastically reducing the worldwide prevalence and leading to the declaration of leprosy's elimination as a public health problem in 2000.[3] However, this triumph has ushered in a new, more nuanced era in leprology. As global health programs succeed and the prevalence of new,

untreated cases declines, the central clinical challenges are shifting.[4] The focus is moving from initial diagnosis and treatment to managing the complex, long-term sequelae in a growing cohort of patients who are officially "cured." Within this new landscape, one of the foremost clinical challenges is the accurate diagnosis of disease recurrence. A true bacteriological relapse, defined as the renewed proliferation of *M. leprae* after the completion of therapy, represents a failure of the initial treatment to achieve a sterile cure.[5] This must be distinguished from the dramatic, immune-mediated inflammatory episodes known as lepra reactions, which can punctuate the disease course at any time—before, during, or even many years after MDT has been completed.[6]

Erythema Nodosum Leprosum (ENL), or Type 2 lepra reaction, sits at the heart of this diagnostic conundrum. This systemic, humorally-mediated inflammatory condition is almost exclusively seen in patients at the lepromatous, high-bacterial-load end of the disease spectrum. It presents acutely with crops of tender, erythematous subcutaneous nodules, often accompanied by debilitating systemic symptoms like fever, neuritis, and arthralgia.[7] While ENL is a well-understood complication during active treatment, its appearance years after a patient has been "released from treatment" (RFT) presents a profound diagnostic dilemma.[8] Is this merely a late reaction, triggered by the slow, protracted clearance of residual antigens from dead bacilli? Or is it a clinical masquerade for something far more sinister: a true bacteriological relapse, where the inflammatory storm is being fueled by a fresh wave of actively multiplying organisms? This distinction is of paramount importance. The literature often discusses late-onset ENL in the context of differentiating it from relapse, creating a diagnostic dichotomy.[9] However, this framework may be too simplistic, as it underemphasizes the possibility that ENL may not be a differential diagnosis but rather a direct clinical consequence of relapse. This gap in clinical understanding can lead to one of two critical errors: treating an active infection with only immunosuppressants, or failing to provide essential anti-inflammatory relief during the re-initiation of antimicrobial therapy.[10]

The novelty of this case report lies in its direct challenge to the conventional separation of late-onset ENL and bacteriological relapse. By providing definitive clinico-histopathological evidence, this study positions ENL not merely as a confounding factor but as a potential and direct clinical harbinger of renewed bacterial proliferation in the post-MDT surveillance period. In the contemporary, post-elimination era of leprosy management, where clinicians will increasingly encounter such complex long-term presentations, this perspective is critically important. Therefore, the aim of this study is twofold: first, to provide definitive histopathological evidence that emphasizes its indispensable role in resolving this critical diagnostic dilemma. Second, by presenting this case, we aim to underscore the critical importance of a dual therapeutic strategy that concurrently manages the acute, damaging inflammation while aggressively treating the underlying infection to prevent long-term morbidity and disability.

2. Case Presentation

A 30-year-old male mechanic presented to our tertiary care dermatology clinic with a distressing three-month history of a painful, progressive, and widespread eruption of skin nodules. His condition was accompanied by significant systemic symptoms, including intermittent fever, debilitating joint and muscle pain, nausea, and vomiting. He had sought prior consultation at a regional hospital, where a presumptive diagnosis of a skin infection or inflammatory dermatosis was made, and a short course of methylprednisolone and doxycycline had been prescribed with only fleeting, minimal relief. A detailed medical history, as summarized in Figure 1, immediately revealed the complexity of the case. The patient had been diagnosed with multibacillary leprosy two years prior and had, by his own account, diligently completed the standard 12-month WHO-MDT regimen. Critically, his post-treatment course

was marked by frequent and severe episodes of painful nodules requiring intermittent steroid therapy, painting a rich picture of a patient struggling with an ongoing, smoldering inflammation that was likely a sign of the brewing relapse.



Figure 1. Patient demographics and clinical history.

On examination, the patient was in significant discomfort, with a resting tachycardia suggestive of a systemic inflammatory state. The dermatological findings were extensive, affecting his face, trunk, and all four limbs with a polymorphic eruption. As detailed in Figure 2, the most striking features were numerous erythematous, warm, and exquisitely tender subcutaneous nodules, characteristic of classic ENL.

This was accompanied by diffuse infiltration of the skin and widespread post-inflammatory hyperpigmentation, marking the sites of previous lesions. The left-hand side of Figure 2 initiates the narrative with the patient's Systemic Status, highlighted in a warm orange box. This section quantifies critical vital parameters: Blood Pressure (BP) recorded at 110/65 mmHg, a Pulse of 145 bpm, a Respiration Rate (Resp) of 20 bpm, and a Body Temperature (Temp) of 36.6 °C. The elevated pulse rate (tachycardia) is a significant finding, often indicative of underlying systemic stress, inflammation, pain, or fever, even if the temperature itself is not overtly febrile at the moment of examination. This objective data provides crucial context for the patient's overall physiological state. Directly below, a red box details the General Appearance, noting the patient was in "moderate distress due to pain and systemic discomfort." This subjective yet critical observation from the clinician complements the objective vital signs, underscoring the patient's immediate clinical suffering and the impact of the disease on their well-being. This information immediately signals the severity of the patient's condition, prompting further investigation. The central and most prominent feature of Figure 2 comprises a series of Clinical Photographs. These images are arranged to provide a comprehensive visual documentation of the patient's dermatological lesions across different body regions. The top row of images displays the patient's facial region from multiple angles (frontal and lateral views), clearly illustrating the widespread involvement of the face. The middle row shows anterior and posterior views of the patient's trunk, revealing the extent of body involvement. The bottom two rows focus on the upper and lower extremities, including the hands and feet, highlighting specific lesions such as nodules and hyperpigmented patches. These photographs are essential for illustrating the morphology, distribution, and overall severity of the skin lesions, allowing for direct visual correlation with the textual descriptions. To the right of the clinical photographs, three distinct blue boxes systematically delineate the Dermatological Assessments by body region. The Facial Region box details "Multiple tender, erythematous nodules," suggesting acute inflammatory processes. "Diffuse infiltration of auricular regions" points to the characteristic involvement of the ears in lepromatous leprosy. "Post-inflammatory hyperpigmentation" indicates resolved or resolving inflammatory lesions, a common sequela in chronic skin conditions. Importantly, the notation "No evidence of madarosis" (loss of eyebrows/eyelashes) is a key differential finding, as madarosis is frequently associated with advanced lepromatous leprosy but was absent in this presentation, which could be relevant for assessing disease progression or previous treatment impact. The Trunk assessment highlights "Numerous, partly confluent nodules," indicating a high burden of disease with lesions merging into larger plaques. The description of a "Polymorphic eruption (macules/papules)" suggests a varied presentation of skin lesions, while "Generalized xerosis (dryness)" points to broader skin involvement and potential systemic effects. Finally, the Extremities box notes "Scattered, discrete nodules & macules," indicating widespread but perhaps less confluent lesions than on the trunk. "Widespread hyperpigmented patches" again suggests a chronic inflammatory process with subsequent pigmentary changes. The crucial observation of "No digital shortening or deformities" is vital, as digital deformities are common sequelae of chronic leprosy, particularly in advanced or inadequately treated cases, thus indicating that this specific, severe complication was not present in this patient at the time of examination. Figure 2 is a highly effective scientific visualization that documents the clinical examination findings. It combines objective vital signs with comprehensive dermatological description.



Figure 2. Physical and dermatological examination findings.

A focused neurological examination was performed to assess for nerve damage, a hallmark of leprosy. Although there was no palpable thickening of the major peripheral nerve trunks, sensory testing revealed significant deficits. As summarized in Figure 3, these findings confirmed ongoing neuropathic processes, a critical indicator of active disease that demanded further investigation.

The clinical picture was highly suggestive of severe ENL, but the history raised a strong suspicion of an underlying relapse. A definitive diagnostic workup was initiated, centered on a 4mm punch biopsy from a newly formed, representative erythematous nodule on the right arm. The results were pivotal. The slit-skin smear revealed a surprisingly high bacterial load, while the histopathology provided the unequivocal, conclusive evidence. Figure 4 presents an exhaustive and visually articulate summary of the critical laboratory and histopathological investigations that underpinned the definitive diagnosis and characterization of a complex case involving relapsed lepromatous leprosy with concurrent Erythema Nodosum Leprosum (ENL).



Figure 3. Neurological assessment findings.

This multi-faceted figure seamlessly integrates a schematic representation of diagnostic procedures with key findings, further substantiated by direct visual evidence from the case report, offering a holistic understanding of the disease's manifestation at the cellular and microbiological levels. The upper panel of Figure 4 systematically details three pivotal investigative modalities: Slit-Skin Smear (Acid-Fast Bacilli - AFB), Histopathology with Hematoxylin and Eosin (H&E) staining, and Histopathology with Fite-Faraco staining. Each modality is presented within a distinct, color-coded card, employing relevant scientific icons to enhance visual appeal and immediate comprehension. The Slit-Skin Smear (AFB) section, highlighted in a vibrant blue, focuses on the direct microbiological examination. It outlines the procedure, noting that samples were procured from both earlobes and an active nodule on the right arm – strategic sites known for high bacillary loads in lepromatous leprosy. Crucially, the investigation revealed a Bacterial Index (BI) of +5. This exceptionally high BI is a profound and alarming finding, given that the patient had reportedly completed Multi-Drug Therapy (MDT) two years prior. Such a significant bacillary load strongly indicated active disease or a robust relapse, challenging the efficacy of previous treatment or suggesting re-infection. Conversely, the Morphological Index (MI) was reported as 0%, suggesting the absence of viable, solid-staining bacilli. However, the accompanying narrative correctly contextualizes this finding, noting that MI, while traditionally used, is now considered an unreliable measure for definitively assessing treatment response or detecting relapse, especially in the context of high BI. This nuanced interpretation underscores the critical importance of integrating multiple diagnostic parameters. Adjacent to the AFB findings, the Histopathology (H&E Stain) section, distinguished by

a rich purple hue, delves into the architectural changes observed in a 4mm punch biopsy. The H&E staining, a cornerstone of dermatopathology, unveiled several characteristic features. Within the dermis, a clear grenz zone was identified – a hallmark pathological feature of lepromatous leprosy where a narrow band of normal collagen separates the epidermis from an underlying inflammatory infiltrate. Below this, a dense, diffuse infiltrate of foamy macrophages, often termed Virchow cells, was observed. These cells, engorged with *Mycobacterium leprae* and their lipid components, are pathognomonic for the lepromatous pole of the disease spectrum. Extending into the subcutis, the biopsy revealed a prominent neutrophilic infiltrate that invaded the fat lobules, unequivocally confirming lobular panniculitis. This specific inflammatory pattern is a classic histological signature of Erythema Nodosum Leprosum (ENL), indicating a Type 2 lepra reaction. Furthermore, evidence of vasculitis was observed, suggesting a systemic inflammatory component often associated with severe ENL reactions. These H&E findings collectively painted a comprehensive picture of active lepromatous disease complicated by a severe immunological reaction. The third upper panel, dedicated to Histopathology (Fite-Faraco Stain) and marked in a striking red, provides specialized insights into the mycobacterial presence. The Fite-Faraco stain is a modified acid-fast stain particularly effective for *M. leprae* due to its ability to preserve the bacilli's waxy cell wall, which can be damaged by conventional Ziehl-Neelsen staining. This investigation confirmed vast numbers of acid-fast bacilli densely packed within macrophages, frequently forming characteristic clusters known as globi. The "Crucial Finding," prominently highlighted within this section, was the identification of intact, solid, rod-shaped bacilli. This is a profoundly significant observation. Unlike fragmented or granular bacilli, which represent non-viable or dead organisms, the presence of solid-staining rods provides irrefutable evidence of viable *M. leprae* and ongoing bacterial proliferation. This finding directly contradicts the 0% MI from the slit-skin smear and definitively confirms active infection and microbiological relapse, guiding subsequent treatment strategies. The key investigative findings, detailed in Table 4, synthesized the patient's history and clinical presentation, leading to the final diagnosis: Relapsed Multibacillary Leprosy, Lepromatous Type, with a concurrent severe Erythema Nodosum Leprosum reaction.

Given the definitive diagnosis of relapse concurrent with severe ENL, the patient was hospitalized to initiate a carefully structured, dual-pronged therapeutic strategy. The management plan, outlined in Figure 5, was designed to rapidly control the damaging inflammation while simultaneously beginning the long-term process of eradicating the active infection. The patient's response was excellent, with a marked improvement in both his skin lesions and systemic symptoms, validating the comprehensive treatment approach. Figure 5 presents a meticulously structured and comprehensive Management and Follow-up Plan, graphically articulating the sophisticated, dual-pronged therapeutic strategy required to address the complex diagnosis of relapsed multibacillary leprosy presenting with a severe Erythema Nodosum Leprosum (ENL) reaction. The first major component, Therapeutic Intervention, highlighted in a commanding orange, details the aggressive, concurrent medical treatments essential for tackling the dual pathology. This pillar is logically subdivided into two crucial subsections. The Anti-Inflammatory protocol is outlined as the first line of defense against the acute, tissue-damaging effects of the ENL reaction. It specifies an initial administration of intravenous Methylprednisolone to achieve rapid and potent suppression of the systemic inflammation. This is followed by a carefully managed transition to oral Prednisolone, with a slow taper over approximately three months.



Figure 4. Laboratory and histopathological investigations.

The rationale is explicit: to swiftly control the inflammatory cascade, thereby preventing irreversible nerve damage (neuritis) and mitigating the patient's severe systemic symptoms. Concurrently, the Antimicrobial strategy targets the root cause of the relapse. It mandates the immediate re-initiation of the full 12-month World Health Organization's Multi-Drug Therapy (WHO-MDT) regimen for multibacillary leprosy, comprising Rifampicin, Clofazimine, and Dapsone. The scientific rationale for this is to eradicate the actively proliferating *Mycobacterium leprae*, thereby eliminating the antigenic source that fuels the inflammatory ENL reaction and ensuring a definitive cure. The second pillar, Patient Care & Monitoring, distinguished by a calming, professional indigo, addresses the essential supportive and long-term management aspects of the patient's journey. This component underscores that treatment extends beyond pharmacology to encompass the patient's overall well-being and a structured plan for assessing therapeutic efficacy over time. The Supportive Care section details measures aimed at symptom management and comfort, including the administration of analgesics for pain control and

intravenous hydration to counteract systemic effects and maintain physiological balance. The rationale emphasizes improving the patient's quality of life during the acute, often debilitating, phase of the illness. Finally, the Follow-up plan establishes a rigorous schedule for post-treatment surveillance. It includes scheduled monthly clinical evaluations to monitor progress and screen for potential adverse effects from the potent medications. Critically, it culminates in a repeat slit-skin smear after the 12-month MDT course is completed. The rationale for this structured follow-up is multifaceted: it ensures patient adherence, allows for safe and effective management of the steroid taper, and provides the objective bacteriological evidence needed to confirm the ultimate success of the retreatment.



Figure 5. Management and follow-up plan.

3. Discussion

The case presented in this report is a profound clinical lesson that unfolds at the complex intersection of microbiology, immunology, and therapeutics. It compels a deep and meticulous dissection of one of the most challenging diagnostic dilemmas in modern leprology: the distinction between a late-stage inflammatory lepra reaction and a true bacteriological relapse of the disease.[11] The accurate navigation of this diagnostic labyrinth is not a mere academic exercise; it carries immense prognostic and therapeutic weight. Figure 6 provides a masterful and scientifically elegant depiction of the complex pathophysiological journey that culminates in the dramatic clinical presentation of relapsed multibacillary leprosy. The narrative begins with the initial state of Post-MDT Dormancy. This stage is fundamental to comprehending the entire phenomenon of relapse. Following the successful completion of a 12-month course of Multi-Drug

Therapy (MDT), the vast majority of *Mycobacterium leprae* are eliminated. However, the treatment does not always achieve a sterile cure.[12] A subpopulation of bacilli, now widely recognized in the scientific community as "persister cells," can survive the therapeutic onslaught. These are not drug-resistant mutants in the classical sense; rather, they are phenotypically drug-tolerant organisms that achieve survival by entering a state of metabolic dormancy. They effectively shut down their replicative and metabolic machinery, rendering them impervious to the bactericidal action of antibiotics that primarily target active cellular processes.From an immunological perspective, this phase is characterized by a fragile truce. The host's immune system, particularly in a patient with lepromatous leprosy who has a specific anergy to *M. leprae*, maintains a permissive environment. The persister bacilli reside silently within host macrophages, which are likely polarized towards an M2 or "alternatively activated" phenotype. These M2 macrophages are ill-equipped to destroy the bacilli and instead function as long-term, silent reservoirs. Clinically, the patient is asymptomatic, has been "released from treatment," and is considered cured. Yet, beneath this veneer of health, a microscopic, viable bacterial population persists, representing a silent, latent threat—a veritable ticking time bomb awaiting the right conditions to re-emerge. The second stage, Bacterial Reactivation, depicted in a vibrant, alarming red-pink, marks the critical turning point in the pathophysiology. For reasons that are still the subject of intense scientific investigation—potentially involving subtle fluctuations in host immune surveillance, intercurrent illness, or other physiological stressors—the dormant persister bacilli awaken. This transition from a quiescent to a metabolically active state is the very definition of a true bacteriological relapse. The icon of a power button poignantly symbolizes this switch from "off" to "on," as the bacteria resume their life cycle. This reactivation is an insidious process. As the bacilli begin to replicate, their numbers increase exponentially. Initially, this renewed proliferation may be subclinical, occurring below the threshold required to elicit noticeable signs or symptoms. The host's immune system, already compromised in its ability to recognize and eliminate *M. leprae*, fails to contain this nascent resurgence. This silent phase of multiplication is crucial to understanding the clinical presentation; it explains why a patient can appear perfectly healthy one moment and then rapidly develop the dramatic and systemic symptoms of ENL. The reactivation is the spark that ignites the fuse, setting the stage for the subsequent inflammatory explosion. It is the unseen event that transforms the silent threat into an active, advancing infection.[13] The narrative progresses to the third stage, Antigen Overload, illustrated with a bright green-teal card and a biohazard icon, signifying a system overwhelmed by pathological material. The uncontrolled bacterial proliferation, a direct consequence of reactivation, leads to a staggering increase in the total bacterial burden within the host. This is quantitatively evidenced in the case by the exceptionally high Bacterial Index (BI) of +5. This is not a slow, protracted release of antigens from dead bacilli, which might explain a mild, late-onset reaction. Instead, this represents a massive, dynamic flood of new mycobacterial antigens being synthesized and released by a vast, replicating bacterial population. Every newly formed bacillus acts as a factory, shedding potent immunogenic components such as the phenolic glycolipid-I (PGL-I), various lipoproteins, and other cell wall constituents into the host's tissues and circulation. The host's reticuloendothelial system, particularly the M2-polarized macrophages, becomes completely saturated and overwhelmed. This state of "Antigen Overload" is the critical fuel for the impending immunological catastrophe. The sheer quantity of foreign material saturates the host's antigen-presenting cells and overwhelms any remaining suppressive mechanisms, making a powerful immune response not just likely, but inevitable. The system is primed for a hyper-inflammatory reaction. The final stage, the ENL Reaction, is depicted in a fiery, dark red, symbolizing

a state of acute crisis and inflammation.[14] This is the clinical climax of the entire pathophysiological sequence. Faced with an overwhelming antigenic load, the lepromatous patient's B-cell dominant (Th2) immune system mounts a vigorous but ultimately dysfunctional response. Vast quantities of circulating anti-*M. leprae* antibodies bind to the newly released antigens, forming massive numbers of immune complexes. According to the classic theory of Type III hypersensitivity, these immune complexes precipitate out of the circulation and deposit in the walls of small blood vessels, particularly within the skin and subcutaneous fat.[15] This deposition triggers the activation of the complement cascade, a powerful arm of the innate immune system. Complement activation generates potent pro-inflammatory molecules and chemoattractants, most notably C5a, which signals an urgent call-to-arms for neutrophils. A massive influx of neutrophils swarms to the sites of immune complex deposition. These activated neutrophils release a toxic arsenal of lytic enzymes, reactive oxygen species, and inflammatory mediators, leading to profound tissue damage. This process manifests as vasculitis (inflammation of blood vessels) and panniculitis (inflammation of subcutaneous fat), which are the histological hallmarks of ENL. Clinically, this immunological explosion is what produces the characteristic tender, erythematous subcutaneous nodules, as well as the systemic symptoms of fever, arthralgia, and malaise, driven by the systemic release of cytokines like Tumor Necrosis Factor-alpha (TNF-α).[16]



Figure 6. Pathophysiology of relapse-induced ENL.

The core of the diagnostic challenge lay in the remarkable ability of Erythema Nodosum Leprosum (ENL) to mimic the clinical signs of a relapse. Both conditions can present with the appearance of new cutaneous nodules. In a relapse, these nodules represent new infiltrations teeming with proliferating bacilli. In ENL, the nodules are immunologically mediated inflammatory foci. To the examining clinician, they can appear strikingly similar. The patient's history provided the first layer of complexity. Having completed a full course of Multidrug Therapy (MDT) two years prior, he was officially "released from treatment" (RFT), a status that implies a cure. In such a patient, the emergence of new lesions would

instinctively trigger the consideration of a late lepra reaction. ENL is well-documented to occur even years after MDT completion, a phenomenon attributed to the extremely slow clearance of a massive antigenic load from the body.[17] In a patient with lepromatous leprosy (LL), the body can harbor trillions of dead or dormant bacilli. The gradual, protracted degradation of these bacterial remnants by the host's reticuloendothelial system can intermittently release antigens, triggering an immune-complex-mediated inflammatory response. This "antigen-processing" hypothesis provides a plausible explanation for late-onset ENL without active infection. The patient's own history of receiving treatment for similar, severe episodes in the preceding two years lent further credence to the possibility of recurrent, late-onset ENL. However, several features of the presentation argued against a simple, uncomplicated reaction and raised a high index of suspicion for relapse. The sheer intensity and widespread nature of the eruption, coupled with severe systemic constitutional symptoms—fever, arthralgia, and profound malaise—suggested an overwhelming inflammatory trigger, one perhaps more potent than the slow leakage of antigens from defunct bacilli. It hinted at a fresh, dynamic source of antigen production, which could only come from renewed bacterial multiplication. This clinical reasoning underscores a fundamental principle in post-MDT surveillance: while late reactions are possible, their severity and systemic impact should be carefully weighed against the possibility of a more dynamic underlying process. The chronicity and severity of this patient's post-RFT inflammatory episodes should have been a significant warning sign that the initial treatment had not achieved a sterile cure.

This clinical suspicion mandated a move beyond history and physical examination to objective bacteriological evidence.[18] The slit-skin smear was the first crucial investigative tool, and its result—a Bacterial Index (BI) of +5—was a startling and pivotal finding. The BI is a logarithmic scale representing the density of acid-fast bacilli in dermal tissue fluid. In a patient who has successfully completed a 12-month course of MDT, the BI is expected to decline steadily, at a rate of approximately 0.5 to 1 log unit per year. Even assuming the patient started with the highest possible BI of +6 at his initial diagnosis, a BI of +5 two years after completing therapy is bacteriologically incongruous with a successful cure. It strongly implies that not only has the bacterial load failed to decrease, but it has likely rebounded significantly. This finding alone shifted the diagnostic probability heavily in favor of a relapse. In stark contrast, the Morphological Index (MI), which quantifies the percentage of solid, uniformly staining (and thus presumably viable) bacilli, was reported as 0%. At first glance, this seems to contradict the diagnosis of a relapse, which should theoretically be characterized by a high MI. However, this discrepancy highlights a critical lesson in leprology: the MI is a notoriously unreliable and often misleading measure of bacterial viability. Its limitations are numerous. It is subject to significant inter-observer variability, sampling error, and staining inconsistencies. More importantly, the entire concept of the MI is predicated on a simplistic assumption that bacterial morphology on light microscopy directly correlates with viability. This assumption breaks down in the context of relapse, which is driven by a unique subpopulation of bacteria known as "persisters." These are dormant or semi-dormant bacilli that have survived the initial onslaught of MDT by entering a state of reduced metabolic activity. These persister cells are often phenotypically drug-tolerant, and their morphology can be indistinguishable from dead, fragmented bacilli. They may not stain uniformly solid, leading to a falsely low or zero MI reading even in the presence of a viable, reactivating population. Therefore, in the context of an unexpectedly high BI, a low MI should never be used to definitively rule out a relapse. The future of viability testing likely lies in molecular methods, such as detecting bacterial 16S ribosomal RNA (a marker of metabolic activity), which may one day provide a more accurate alternative to the archaic MI.

Given the conflicting bacteriological data, it was the skin biopsy, subjected to meticulous

histopathological analysis, that ultimately provided the unequivocal and definitive resolution. The Hematoxylin-Eosin (H&E) stained sections beautifully illustrated the dual pathology. On one hand, the tissue architecture was classic lepromatous leprosy. There was a dense, diffuse infiltrate throughout the dermis composed of sheets of large macrophages with abundant, vacuolated, lipid-rich cytoplasm—the classic foamy Virchow cells. A clear, acellular subepidermal "grenz zone" was also present. Superimposed on this chronic granulomatous background was the unmistakable signature of an acute ENL reaction: a florid, neutrophil-rich inflammatory infiltrate extending deep into the subcutaneous fat lobules (lobular panniculitis) and centered around blood vessels (vasculitis). While the H&E stain set the stage, it was the Fite-Faraco (FF) stain that delivered the final, conclusive verdict. This special stain is specifically designed to detect the lipid-rich cell wall of mycobacteria. The FF-stained sections were teeming with acid-fast bacilli, confirming the high bacterial load suggested by the BI. But the most crucial observation lay in the morphology of these stained bacilli.[19] Amidst a sea of fragmented and granular bacterial debris—representing the dead bacilli from the previous infection—the pathologist could clearly identify numerous intact, solid, uniformly stained, rod-shaped bacilli. These solid-staining forms are the universally accepted histopathological representation of metabolically active, viable organisms. Their presence was the "smoking gun," the irrefutable proof of active bacterial proliferation. This finding definitively confirmed a true bacteriological relapse. It also profoundly re-contextualized the ENL; it was not a reaction to old, dead antigens but a direct immunological consequence of the new wave of live, multiplying bacilli.

To fully grasp the significance of this case, one must delve into the intricate immunopathophysiology that connects relapse and ENL. The classic understanding of ENL pathogenesis is centered on the immune-complex pathway. Lepromatous leprosy represents a state of specific immune tolerance to *M. leprae*, where the cell-mediated Th1 response is suppressed, and the humoral Th2 response dominates. This leads to high levels of circulating anti-*M. leprae* antibodies. When a large amount of mycobacterial antigen is released, these antibodies form immune complexes that deposit in tissues, activate complement, and trigger a massive, neutrophil-driven inflammatory cascade orchestrated by cytokines like TNF-α. However, a more modern perspective centers on the macrophage itself as the primary driver. The host's immune response can polarize macrophages into two main states: a "classically activated" M1 state, which is pro-inflammatory and bactericidal, and an "alternatively activated" M2 state, which is anti-inflammatory and permissive for intracellular pathogens. Lepromatous leprosy is a quintessential M2-dominant disease. The macrophages, locked in this M2 state, are unable to kill the phagocytosed bacilli, becoming passive incubators. A relapse signifies a fundamental failure of the host to ever switch to a protective M1 phenotype. In this context, ENL can be re-envisioned. It is not just a passive consequence of antibody deposition. It is a dysfunctional, hyper-inflammatory response triggered by these M2 macrophages when they are completely overwhelmed by the new wave of uncontrolled bacterial replication from the reactivated persister cells. The release of bacterial products from these multiplying organisms triggers a panic response, leading to the massive production of pro-inflammatory cytokines and chemokines that recruit neutrophils, resulting in the acute tissue damage characteristic of ENL. In our patient, the relapse was the spark, and the dysfunctional M2-macrophage-driven inflammation was the resulting wildfire.[20]

This deep understanding of the pathophysiology directly informs the therapeutic strategy. The management of this patient was a delicate balancing act, requiring a dual-pronged attack. The first priority was to extinguish the damaging inflammatory fire of ENL. The intense inflammation, particularly if it involves nerves, can lead to rapid and irreversible

sensory and motor loss. High-dose systemic corticosteroids are the mainstay of treatment, acting as potent, non-specific anti-inflammatory agents. However, treating the inflammation alone would be a grave error. The second, and more fundamental, therapeutic imperative was to treat the root cause: the active bacterial infection. This required the immediate re-initiation of the full 12-month WHO-MDT regimen. This concurrent administration of potent immunosuppressants and effective antimicrobials is the logical and necessary approach. The therapeutic landscape for severe or recurrent ENL is broader still. Thalidomide is a highly effective second-line agent, potently inhibiting TNF-α, but its use is tightly controlled due to its severe teratogenicity. Clofazimine, a component of MDT, also possesses valuable anti-inflammatory properties. For the most refractory cases, biologic agents that target specific cytokines are being explored, but their use in the context of an active infection is fraught with risk. In this case, the classic combination of corticosteroids and MDT proved highly effective.

4. Conclusion

This case of relapsed lepromatous leprosy, dramatically unmasked by a severe episode of ENL two years after treatment completion, establishes an important diagnostic principle: in the context of post-MDT multibacillary leprosy, unexplained or severe inflammation should be considered a sign of active infection until proven otherwise. This "inflammation equals infection until proven otherwise" principle mandates a low threshold for definitive, tissue-based investigation and represents the safest and most effective strategy for the long-term care of these complex patients. The journey to the correct diagnosis in this patient cements the role of histopathology not as an ancillary test, but as an indispensable cornerstone in resolving the complex dilemma of relapse versus reaction. The visualization of intact, solid-staining, viable bacilli is the definitive evidence that transforms the diagnostic landscape. Ultimately, this case advocates for a paradigm shift in the post-MDT surveillance of high-BI lepromatous patients. The onset of ENL, at any point following RFT, should trigger an immediate and thorough investigation for relapse, with a proactive approach that is essential to prevent misdiagnosis, avert progressive disability, and advance the ultimate goal of leprosy eradication.

5. References

1. Feitosa da Silva Barboza M, de Andrea Hacker M, Maria Sales A, Fontoura Rodrigues D, Pedrosa Marques D, José Ciryllo Silva Noya D, et al. Neutrophilic leukocytosis and erythema nodosum leprosum in leprosy: insights from a retrospective observational study. Front Immunol. 2024; 15: 1368460.
2. Setyono A, Rusyati LMM, Karmila IGAAD, Winaya KK, Praharsini IGAA, Suryawati N, et al. High serum platelet-to-lymphocyte ratio as a risk factor for severe erythema nodosum leprosum. Indones J Biomed Sci. 2024; 18(2): 179–82.
3. Sunil Kumar S, Sivannan S, Balasubramaniyam S, Elumalai K. Erythema nodosum leprosum in a patient with lepromatous leprosy: a case report. J Acute Dis. 2024; 13(4): 161–4.
4. Malhi K, Singla L, Singh A, Kaur S. A life-threatening consequence of erythema nodosum leprosum. Indian J Dermatol Venereol Leprol. 2024; (1): 1–4.
5. Patel V, Ahuja R, Arava SK, Khandpur S, Bhari N, Gupta V, et al. A retrospective study of the histopathological spectrum of erythema nodosum leprosum. Indian Dermatol Online J. 2024; 15(5): 779–86.
6. Kaur M, Budania A, Agrawal A, Lahoria U. Severe postural hypotension and sinus bradycardia with thalidomide in patients with erythema nodosum leprosum. BMJ Case Rep. 2024; 17(9): e256303.
7. Mansilla-Polo M, Abril-Pérez C, Martín-Torregrosa D, Botella-Estrada R, Torres-Navarro I. Successful treatment of erythema

nodosum leprosum with upadacitinib and roflumilast. Int J Dermatol. 2025; 64(1): 164–6.

8. Rathod N, Toshniwal SS, Chavhan R, Acharya S, Chiwhane A. Hypertensive crisis and myocardial infarction with non-obstructive coronary arteries in a leprosy patient with erythema nodosum leprosum: The role of corticosteroids. Cureus. 2025; 17(1): e77041.
9. Nagarajan HDP, Kamaraj B, Selvanathan K, Kumar S, Gaidhane S, Sah S, et al. Necrotic erythema nodosum leprosum - A case of severe lepromatous reaction in a multibacillary leprosy patient. IDCases. 2025; 39(e02152): e02152.
10. Ariani T, Putri CM. A rare presentation of type 2 lepra reaction: necrotizing erythema nodosum leprosum with extensive ulceration. BioSci Med J Biomed Transl Res. 2025; 9(3):6654–66.
11. Zimmerman HM, Frankel RI, Seid JD, Karagenova R, Saksena S, Liang BX, et al. Utility of the Erythema Nodosum Leprosum International Study severity scale for erythema nodosum leprosum: a clinically supported critical appraisal. Am J Trop Med Hyg. 2025; 113(4): 731–3.
12. Malhi K, Hanumanthu V, Singh S, Bishnoi A, Chatterjee D, Bansal R, et al. Scleromalacia perforans: a rare and sight-threatening complication of chronic erythema nodosum leprosum. Trans R Soc Trop Med Hyg. 2025; 119(2): e1–3.
13. Maciel-Fiuza MF, Sbruzzi RC, Feira MF, Costa P do SS, Bonamigo RR, Vettorato R, et al. Influence of Cytokine-Related genetic variants in TNF, IL6, IL1β, and IFNγ genes in the thalidomide treatment for Erythema nodosum leprosum in a Brazilian population sample. Hum Immunol. 2025; 86(2): 111260.
14. Balasuriya CD, Gamaarachchi D, Jayasinghe PA. Erythema nodosum leprosum presenting as fever of unknown origin. Asian J Internal Med. 2025; 4(1): 78–81.
15. Ianhez M, Gomes CM, Grana AG, Talhari C, Miot HA. Novel drugs for the management of recalcitrant erythema nodosum leprosum. J Eur Acad Dermatol Venereol. 2025; 39(6): e564–7.
16. Factors associated with the severity of erythema nodosum leprosum reactions. J Gen-Proced Dermatol Venereol Indones. 2025; 9(1).
17. Singh GK, Srivastava S, Das P, Arora S, Khetan A. Leprosy relapse presenting with pustular erythema nodosum leprosum in a case of HIV. Indian Dermatol Online J. 2025; 16(4): 681–3.
18. Perazzoli S, Fiuza MF, De Moraes PC, Heck R, Vianna FS, Bonamigo RR. Prevalence of genetic variants in SERPINB2 and PKNOX1 genes in erythema nodosum leprosum patients from southern Brazil. J Infect Dev Ctries. 2025; 19(7): 1083–8.
19. Darmasatria R, Ariani T, Rizal Y, Gustia R, Izrul I. The 15-year shadow: Borderline lepromatous leprosy with erythema Nodosum Leprosum following prolonged treatment default. BioSci Med J Biomed Transl Res. 2025; 9(10): 9048–63.
20. Walker SL, Sales AM, Butlin CR, Shah M, Maghanoy A, Lambert SM, et al. A leprosy clinical severity scale for erythema nodosum leprosum: an international, multicentre validation study of the ENLIST ENL Severity Scale. PLoS Negl Trop Dis. 2017; 11(7): e00057.